Brandywine Global Investment Management LLC Makes New $3.58 Million Investment in The Cooper Companies, Inc. $COO

Brandywine Global Investment Management LLC purchased a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 43,734 shares of the medical device company’s stock, valued at approximately $3,584,000.

Several other hedge funds also recently modified their holdings of the company. Manchester Capital Management LLC boosted its stake in shares of Cooper Companies by 34.0% during the 4th quarter. Manchester Capital Management LLC now owns 1,666 shares of the medical device company’s stock worth $137,000 after purchasing an additional 423 shares during the last quarter. Capital International Inc. CA boosted its stake in shares of Cooper Companies by 22.9% during the 4th quarter. Capital International Inc. CA now owns 118,210 shares of the medical device company’s stock worth $9,688,000 after purchasing an additional 22,054 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Cooper Companies during the 4th quarter worth about $75,000. Havemeyer Place LP acquired a new stake in shares of Cooper Companies during the 4th quarter worth about $2,429,000. Finally, Parallel Advisors LLC boosted its stake in shares of Cooper Companies by 72.8% during the 4th quarter. Parallel Advisors LLC now owns 1,583 shares of the medical device company’s stock worth $130,000 after purchasing an additional 667 shares during the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Recent commentary highlighted The Cooper Companies as a strong long-term growth name, with Zacks calling it a top growth stock and Seeking Alpha noting potential for an analyst upgrade as valuation improves. Article Title
• Positive Sentiment: Analysts and market commentary also pointed to the company’s demand growth and prior quarterly earnings beat, which can reinforce confidence in revenue momentum. Article Title
• Neutral Sentiment: One article noted that Cooper has strong revenue growth, especially in CooperVision, but also said litigation charges tied to embryo culture media recalls have weighed on reported profitability; these issues do not appear to change the long-term outlook materially. Article Title
• Negative Sentiment: Some analysis still argues The Cooper Companies needs stronger return on equity and profit margins, which may temper enthusiasm despite solid sales trends. Article Title

Cooper Companies Price Performance

COO opened at $67.69 on Thursday. The company’s 50 day simple moving average is $64.94 and its 200 day simple moving average is $74.45. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The Cooper Companies, Inc. has a 1 year low of $58.89 and a 1 year high of $89.83. The stock has a market capitalization of $13.20 billion, a PE ratio of 57.36, a P/E/G ratio of 1.80 and a beta of 0.87.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period last year, the company earned $0.96 earnings per share. The company’s quarterly revenue was up 7.9% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 4.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on COO shares. Stifel Nicolaus decreased their price target on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. The Goldman Sachs Group set a $61.00 price target on shares of Cooper Companies in a research note on Wednesday, May 27th. Needham & Company LLC decreased their target price on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, June 5th. Finally, Rothschild & Co Redburn cut shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a research report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $82.64.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.